NCT06408623View on ClinicalTrials.gov

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2026

Conditions

Liver Cancer

Interventions

DRUG

chidamide combined with Sintilimab and bevacizumab

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06408623 - Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer | Biotech Hunter | Biotech Hunter